Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Key Takeaway: ClaimsFiler has announced a reminder for investors in Corcept Therapeutics, who incurred losses over $100,000, regarding the deadline for participating as lead plaintiff in a securities class action lawsuit. The lawsuit claims that Corcept and its executives failed to disclose crucial information about the potential FDA approval for their product candidate, relacorilant. Following the FDA's issuance of a Complete Response Letter on December 31, 2025, which indicated insufficient evidence of effectiveness, Corcept's share price fell dramatically. The lawsuit is currently pending in California's Northern District Court.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept disclosed the FDA issued a Complete Response Letter for relacorilant, hindering its approval.
  • The price of Corcept's shares dropped significantly by over 50% following the FDA's negative decision.

Full Press Release Details

NEW ORLEANS, March 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

Investors must file lead plaintiff applications by April 21, 2026.

What triggered the securities class action against Corcept?

The action was triggered by Corcept's disclosure of a Complete Response Letter from the FDA.

How much did Corcept's stock price drop?

Corcept's share price dropped by $35.40, or 50.4%, after the FDA's announcement.

Where can investors find more information about the case?

Investors can visit https://claimsfiler.com/cases/nasdaq-cort-1/ for more details.

Who is representing investors in this lawsuit?

Lawyers at Kahn Swick & Foti, LLC are available to discuss legal options.

Last updated: Mar 26, 2026